CROI 2005, Poster # 595



HIV and Non-HIV-related Deaths and Their Relationship to Immunodeficiency: The D:A:D Study

Rainer Weber*1, Nina Friis-Møller2, Caroline A Sabin3, Peter Reiss4, Antonella D'Arminio Monforte5, Francois Dabis6, Wafaa El-Sadr7, Stephane De Wit8, Linda Morfeldt9, Matthew G Law10, Christian Pradier¹¹, Gonzalo Calvo¹², Christian Holkmann-Olsen¹³, Andrew N Phillips³ and Jens D Lundgren² on behalf of the D:A:D Study Group

*Swiss HIV Cohort Study (SHCS), Switzerland; *Copenhagen HIV Program (CHIP), Denmark; *Royal Free and University College, London, UK; *ATHENA Cohort Study Group, The Netherlands; *ICONA, Italy; *Aquitaine Cohort, France; *Community Programs for Clinical Research on AIDS (CPCRA), USA; 8St-Pierre Cohort, Belgium; PHVUS, Sweden; Paustralian HIV Observational Database (AHOD), Australia; Plice Cohort, France; PASS, Spain; and PauroSIDA, Copenhagen HIV Program, Denmark

Rainer Weber, M.D. Division of Infectious Diseases University Hospital CH-8091 Zurich Switzerland Tel:+41-1-255 38 26 Fax:+41-1-255 32 91 E-mail:infweb@usz.unizh.ch

BACKGROUND

Deaths in people with HIV infection are often classified according to whether they are thought to be "HIV-related" or not. We studied whether deaths generally thought to be unrelated to HIV were more likely to occur in people with a low CD4 count.

METHODS

D:A:D is a prospective study of 23,441 patients from 11 existing cohorts in Europe, Australia, and the USA. Detailed information on deaths occurring between the initiation of D:A:D in 2000 and February 2004 was collected.

Causes of death were coded centrally in to the following categories according to the *underlying* cause of death:

- •HIV/AIDS
- •Invasive bacterial infection
- •Malignancy, non-AIDS, non-hepatitis
- •Chronic viral hepatitis
- •Liver failure (other)
- Myocardial infarction, definite or possible
- Stroke
- •Other cardiovascular disease
- •Other heart disease
- Complications to diabetes mellitus Pancreatitis
- •Renal failure
- Drug overdose
- Suicide •Euthanasia
- •Other, specify Unknow

For the purpose of these analyses, the following groupings were applied: HIV/AIDS-related:


- •HIV/AIDS
- •Invasive bacterial infection Futhanasia
- Liver-related:
- •Chronic viral hepatitis


Malignancy-related:

•Malignancy, non-AIDS, non-hepatitis

- Myocardial infarction, definite or possible
- •Other cardiovascular disease
- •Other heart disease


Relative rates of factors associated with death were calculated using Poisson regression, adjusted for HIV RNA, age, cohort, race and smoking status.





CD4 count	Number	PY	Rate (95% CI) per 1000 PY	Rate ratio* (95% CI)
< 50		1657	126.7 (109.6-143.9)	96.4 (61.6-150.7)
50-		1711	32.1 (23.7-40.6)	28.5 (17.6-46.0)
100-		6044	13.7 (10.8-16.7)	13.6 (8.7-21.2)
200-		15421	3.1 (2.2-3.9)	3.4 (2.1-5.4)
350-		17578	1.7 (1.1-2.3)	1.9 (1.2-3.3)
500-	28	34370	0.8 (0.5-1.1)	1.00

Liver-related Deaths								
CD4 count	Number	PY	Rate (95% CI) per 1000 PY	Rate ratio* (95% CI)				
		1657	12.7 (7.3-18.1)	26.6 (12.9-54.7)				
50-			11.1 (6.1-16.1)	22.2 (11.2-44.3)				
100-	44	6044	7.3 (5.1-9.4)	13.5 (7.5-24.3)				
200-		15421	3.2 (2.3-4.1)	6.5 (3.7-11.4)				
350-		17578	1.2 (0.7-1.7)	2.5 (1.3-4.7)				
500-		34370	0.5 (0.3-0.8)	1.00				





Heart-related Deaths							
CD4 count	Number	PY	Rate (95% CI) per 1000 PY	Rate ratio* (95% CI)			
		1657	3.6 (1.3-7.9)	3.1 (1.2-8.2)			
		1711	2.9 (0.9-6.8)	2.1 (0.8-5.5)			
100-		6044	2.8 (1.6-4.5)	1.9 (1.1-3.5)			
200-		15421	1.8 (1.1-2.5)	1.3 (0.8-2.2)			
350-		17578	1.0 (0.6-1.6)	0.8 (0.4-1.4)			
500-		34370	1.1 (0.7-1.4)	1.00			

- Over a study period of 76,893 person-years of follow-up (PY), 1248 (5.3%)
- The incidence of deaths was 1.6/100 PY.
- 82% had used ART prior to enrolment for a median of 2.8 years.
- The leading cause of death was AIDS (30%), followed by liver-related deaths (14%, of which 79% were associated with chronic viral hepatitis), deaths from heart disease (including cardiovascular disease, 9%), and deaths from non-AIDS malignancies (8%) (Table 1).
- The proportion of deaths from these causes remained stable over time
- HIV/AIDS-related death was, as expected, strongly associated with the latest CD4 cell count (Table 2).
- The adjusted relative rate of death from an AIDS-related cause in patients with a latest CD4 count < 50 cells/μL versus > 500 cells/μL was 96.4 ([95% CI 61.6 to 150.7], p < 0.0001).
- However, other causes of death were also associated with immunofunction (Tables 3-5; Figure 2).
- Liver-related deaths (relative rate 26.6 [12.9 to 54.7], p <0.0001; Table 3) and deaths from non-AIDS malignancies (23.5 [9.4 to 58.7], p < 0.0001; Table 4) were similarly strongly associated with latest CD4 count. The relationship between the CD4 cell count and death from heart disease was less strong but remained significant (3.1 [1.2 to 8.2], p = 0.02; Table 5).
- The trends persisted after considering the associations between death from each cause and the CD4 count measured 3 and 6 months prior to death (illustrated for liver-related deaths in Figure 3; this figure also include a sensitivity analyses excluding 17 patients who had HIV/AIDS as a contributory cause of death ('liver_sens')).

CONCLUSIONS

- Deaths from causes generally thought to be non-HIV-related are more likely to occur in persons with lower rather than higher
- Although residual confounding cannot be ruled out, low CD4 cell numbers seem to contribute to a proportion of such deaths, implying that immunodeficiency may be relevant to their pathogenesis.
- It appears that deaths occurring in persons with a very low CD4 count can only be categorized as non-HIV-related if there is clear evidence that the patient's immunodeficiency did not contribute to the death.
 - o These findings were part of the basis for creating a new system for coding causes of death, including an assessment of immunodeficiency relatedness, the CoDe project (web: www.cphiv.dk/CoDe)





Acknowledgements

Cohort principal investigators: G Calvo*, F Dabis*, W El Sadr* O Kirk*, M Law*, A d'Arminio Monforte*

Cohort principal investigators: G Calvor, F Dabis*, W El Sadr* O Kirk*, M Law*, A d'Arminio Montorte*, L Morfeld*, C Pradier*, P Reiss*, R Weber*, S De Wit*
Cohort Coordinators and data managers: S Zaheri, I van Valkengoed, R Thiébaut, E Balestre, K Petoumeno S Mateu, F Torres, B Sommereijns, B Poll,
G Thompsen, I Kjær, P Pezzotti, E Fontas, C Caissotti, A Sundström, G Thulin, M Rickenbach, O Keiser Statisticians: CA Sabin, AM Phillips*
Community representative: S Collins*

Statisticians: LA Saoin, AN PHILLIPS *
Community representatives Collins *
D:AD Coordinating office: N Friis-Moller, A Sawitz, JD Lundgren*
Steering Committee: Members indicated w/*; c chair;
Additional members: E Loeliger*, T Mertenskoetter*,, R Tressler*, I Weller *
Funding: 'Oversight Committee for The Evaluation of Metabolic Complications of HAART with representatives from academia, patient community, FDA, EMA: And a consortium of 'Abbott, Agouron, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, Pfizer, and Hoffman-La Roche'